Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching
- PMID: 18378894
- PMCID: PMC2311338
- DOI: 10.1073/pnas.0710799105
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching
Abstract
Many pathogens are sheltered from host immunity by surface polysaccharides that would be ideal as vaccines except that they are too similar to host antigens to be immunogenic. The production of functional IgG is a desirable response to vaccines; because IgG is the only isotype that crosses the placenta, it is of particular importance in maternal vaccines against neonatal disease due to group B Streptococcus (GBS). Clinical studies found a substantially lower proportion of IgG-relative to IgM-among antibodies elicited by conjugates prepared with purified GBS type V capsular polysaccharide (CPS) than among those evoked by CPSs of other GBS serotypes. The epitope specificity of IgG elicited in humans by a conjugate prepared with type V CPS is for chemically desialylated type V CPS (dV CPS). We studied desialylation as a mechanism for enhancing the ability of type V CPS to induce IgM-to-IgG switching. Desialylation did not affect the structural conformation of type V CPS. Rhesus macaques, whose isotype responses to GBS conjugates match those of humans, produced functionally active IgG in response to a dV CPS-tetanus toxoid conjugate (dV-TT), and 98% of neonatal mice born to dams vaccinated with dV-TT survived lethal challenge with viable GBS. Targeted chemical engineering of a carbohydrate to create a molecule less like host self may be a rational approach for improving other glycoconjugates.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.J Clin Invest. 1996 Nov 15;98(10):2308-14. doi: 10.1172/JCI119042. J Clin Invest. 1996. PMID: 8941648 Free PMC article. Clinical Trial.
-
Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.Vaccine. 2000 Nov 22;19(7-8):850-61. doi: 10.1016/s0264-410x(00)00226-7. Vaccine. 2000. PMID: 11115709
-
Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.J Infect Dis. 2004 Mar 15;189(6):1103-12. doi: 10.1086/382193. Epub 2004 Mar 1. J Infect Dis. 2004. PMID: 14999615 Clinical Trial.
-
Vaccines to prevent neonatal GBS infection.Semin Neonatol. 2002 Aug;7(4):315-23. doi: 10.1016/s1084-2756(02)90114-4. Semin Neonatol. 2002. PMID: 12401301 Review.
-
Glycoconjugate vaccines to prevent group B streptococcal infections.Expert Opin Biol Ther. 2003 Sep;3(6):975-84. doi: 10.1517/14712598.3.6.975. Expert Opin Biol Ther. 2003. PMID: 12943456 Review.
Cited by
-
Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.Nat Commun. 2017 Nov 17;8(1):1601. doi: 10.1038/s41467-017-01640-y. Nat Commun. 2017. PMID: 29150603 Free PMC article.
-
Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathways.Infect Immun. 2013 Sep;81(9):3106-18. doi: 10.1128/IAI.00113-13. Epub 2013 Jun 17. Infect Immun. 2013. PMID: 23774593 Free PMC article.
-
A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.J Infect Dis. 2019 Jun 5;220(1):105-115. doi: 10.1093/infdis/jiz062. J Infect Dis. 2019. PMID: 30778554 Free PMC article.
-
Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII.J Biol Chem. 2014 Aug 22;289(34):23437-48. doi: 10.1074/jbc.M114.567974. Epub 2014 Jul 2. J Biol Chem. 2014. PMID: 24990951 Free PMC article.
-
Evaluation of the Immunomodulatory Properties of Streptococcus suis and Group B Streptococcus Capsular Polysaccharides on the Humoral Response.Pathogens. 2017 Apr 20;6(2):16. doi: 10.3390/pathogens6020016. Pathogens. 2017. PMID: 28425925 Free PMC article.
References
-
- Adams WG, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. J Am Med Assoc. 1993;269:221–226. - PubMed
-
- Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006) Vaccine. 2007;25:2194–2212. - PubMed
-
- Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Ped Infect Dis J. 2004;23:S274–S279. - PubMed
-
- Suzuki M, Angata K, Nakayama J, Fukuda M. Polysialic acid and mucin type o-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion. J Biol Chem. 2003;278:49459–49468. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources